WO1996003141A1 - Pharmaceutical compositions comprising a chimaeric tnf binding protein - Google Patents

Pharmaceutical compositions comprising a chimaeric tnf binding protein Download PDF

Info

Publication number
WO1996003141A1
WO1996003141A1 PCT/EP1995/002788 EP9502788W WO9603141A1 WO 1996003141 A1 WO1996003141 A1 WO 1996003141A1 EP 9502788 W EP9502788 W EP 9502788W WO 9603141 A1 WO9603141 A1 WO 9603141A1
Authority
WO
WIPO (PCT)
Prior art keywords
tnf
binding protein
chimaeric
tnf binding
cells
Prior art date
Application number
PCT/EP1995/002788
Other languages
English (en)
French (fr)
Inventor
Robert Fredrick Geoffrey Booth
Werner Lesslauer
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Priority to EP95926902A priority Critical patent/EP0772449A1/en
Priority to PL95318501A priority patent/PL318501A1/xx
Priority to JP8505421A priority patent/JPH09508140A/ja
Priority to BR9508419A priority patent/BR9508419A/pt
Priority to AU31119/95A priority patent/AU3111995A/en
Publication of WO1996003141A1 publication Critical patent/WO1996003141A1/en
Priority to NO970264A priority patent/NO970264L/no
Priority to FI970247A priority patent/FI970247A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
PCT/EP1995/002788 1994-07-22 1995-07-15 Pharmaceutical compositions comprising a chimaeric tnf binding protein WO1996003141A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP95926902A EP0772449A1 (en) 1994-07-22 1995-07-15 Pharmaceutical compositions comprising a chimaeric tnf binding protein
PL95318501A PL318501A1 (en) 1994-07-22 1995-07-15 Pharmaceutic compositions containing a tnc bonding chimeric protein
JP8505421A JPH09508140A (ja) 1994-07-22 1995-07-15 キメラｔｎｆ結合タンパク質を含有する医薬組成物
BR9508419A BR9508419A (pt) 1994-07-22 1995-07-15 Composições farmacêuticas compreendendo uma proteina de ligação de tnf quinerica
AU31119/95A AU3111995A (en) 1994-07-22 1995-07-15 Pharmaceutical compositions comprising a chimaeric tnf binding protein
NO970264A NO970264L (no) 1994-07-22 1997-01-21 Farmasöytiske blandinger omfattende et chimærisk TNF-bindende protein
FI970247A FI970247A (fi) 1994-07-22 1997-01-21 Farmaseuttisia koostumuksia, jotka sisältävät kimeerisen TNF:ää sitovan proteiinin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94111455 1994-07-22
EP94111455.5 1994-07-22

Publications (1)

Publication Number Publication Date
WO1996003141A1 true WO1996003141A1 (en) 1996-02-08

Family

ID=8216138

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/002788 WO1996003141A1 (en) 1994-07-22 1995-07-15 Pharmaceutical compositions comprising a chimaeric tnf binding protein

Country Status (11)

Country Link
EP (1) EP0772449A1 (pt)
JP (1) JPH09508140A (pt)
AU (1) AU3111995A (pt)
BR (1) BR9508419A (pt)
CA (1) CA2195665A1 (pt)
CZ (1) CZ283219B6 (pt)
FI (1) FI970247A (pt)
HU (1) HUT76666A (pt)
NO (1) NO970264L (pt)
PL (1) PL318501A1 (pt)
WO (1) WO1996003141A1 (pt)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041895A2 (en) * 1996-05-08 1997-11-13 F. Hoffmann-La Roche Ag TREATMENT OF ASTHMA WITH TNFR-Ig
WO1998025967A1 (en) * 1996-12-12 1998-06-18 Genentech, Inc. Hvem polypeptides and uses thereof
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
JP2002514048A (ja) * 1996-07-09 2002-05-14 アムジェン インコーポレイテッド 短縮型可溶性腫瘍壊死因子ｉ型およびｉｉ型レセプター
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
WO2003011323A1 (en) * 2001-07-30 2003-02-13 Genset S.A. Agonists and antagonists of contabix for use in the treatment of metabolic disorders
WO2002068455A3 (en) * 2001-02-23 2003-09-18 Immunex Corp Efficient recovery of correctly refolded proteins
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US7208577B2 (en) 1995-11-22 2007-04-24 Amgen, Inc. Methods of increasing lean tissue mass using OB protein compositions
US7544492B1 (en) 1994-08-17 2009-06-09 The Rockefeller University OB polypeptides, modified forms and derivatives
US7674453B2 (en) 2002-02-06 2010-03-09 Ares Trading Sa Tumor necrosis factor combined with interferon in demyelinating diseases
US7906638B2 (en) 1996-12-09 2011-03-15 Regents Of The University Of California Chimeric nucleic acids encoding polypeptides comprising CD70 and Fas ligand domains
US7928205B2 (en) 2004-10-22 2011-04-19 Amgen Inc. Methods for refolding of recombinant antibodies
US7964712B2 (en) 2001-12-06 2011-06-21 The Regents Of The University Of California Chimeric nucleic acids encoding polypeptides comprising TNF alpha, CD70 and FAS ligand domains
WO2016029043A1 (en) 2014-08-21 2016-02-25 The General Hospital Corporation Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002531902A (ja) 1998-11-27 2002-09-24 シナプティックス （ユーケー）リミテッド 位置センサ

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0417563A2 (de) * 1989-09-12 1991-03-20 F. Hoffmann-La Roche Ag TNF-bindende Proteine
WO1992001472A1 (en) * 1990-07-19 1992-02-06 Celltech Limited Multivalent anti-cytokine immunoglobulins
EP0512528A2 (en) * 1991-05-07 1992-11-11 Yeda Research And Development Company, Ltd. Pharmaceutical compositions comprising an anticytokine
WO1994006476A1 (en) * 1992-09-15 1994-03-31 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
WO1994008609A1 (en) * 1992-10-15 1994-04-28 Dana-Farber Cancer Institute, Inc. TREATMENT OF INSULIN RESISTANCE IN OBESITY LINKED TYPE II DIABETES USING ANTAGONISTS TO TNF-α FUNCTION

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0417563A2 (de) * 1989-09-12 1991-03-20 F. Hoffmann-La Roche Ag TNF-bindende Proteine
WO1992001472A1 (en) * 1990-07-19 1992-02-06 Celltech Limited Multivalent anti-cytokine immunoglobulins
EP0512528A2 (en) * 1991-05-07 1992-11-11 Yeda Research And Development Company, Ltd. Pharmaceutical compositions comprising an anticytokine
WO1994006476A1 (en) * 1992-09-15 1994-03-31 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
WO1994008609A1 (en) * 1992-10-15 1994-04-28 Dana-Farber Cancer Institute, Inc. TREATMENT OF INSULIN RESISTANCE IN OBESITY LINKED TYPE II DIABETES USING ANTAGONISTS TO TNF-α FUNCTION

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WOOLEY P.H. ET AL.: "Influence of a Recombinant Human Soluble Tumor Necrosis Factor Receptor FC Fusion Protein on Type II Collagen-Induced Arthritis in Mice", JOURNAL OF IMMUNOLOGY, vol. 151, no. 11, 1 December 1993 (1993-12-01), BALTIMORE US, pages 6602 - 6607 *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US7544492B1 (en) 1994-08-17 2009-06-09 The Rockefeller University OB polypeptides, modified forms and derivatives
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US7112659B2 (en) 1995-11-22 2006-09-26 Amgen, Inc. OB fusion protein compositions and methods
US7208577B2 (en) 1995-11-22 2007-04-24 Amgen, Inc. Methods of increasing lean tissue mass using OB protein compositions
US8080254B2 (en) 1995-11-22 2011-12-20 Amgen, Inc. OB fusion protein compositions and methods
US7718400B2 (en) 1995-11-22 2010-05-18 Amylin Pharmaceuticals, Inc. Methods of increasing lean tissue mass using OB protein compositions
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
WO1997041895A2 (en) * 1996-05-08 1997-11-13 F. Hoffmann-La Roche Ag TREATMENT OF ASTHMA WITH TNFR-Ig
WO1997041895A3 (en) * 1996-05-08 1998-03-12 Hoffmann La Roche TREATMENT OF ASTHMA WITH TNFR-Ig
JP2002514048A (ja) * 1996-07-09 2002-05-14 アムジェン インコーポレイテッド 短縮型可溶性腫瘍壊死因子ｉ型およびｉｉ型レセプター
US7906638B2 (en) 1996-12-09 2011-03-15 Regents Of The University Of California Chimeric nucleic acids encoding polypeptides comprising CD70 and Fas ligand domains
WO1998025967A1 (en) * 1996-12-12 1998-06-18 Genentech, Inc. Hvem polypeptides and uses thereof
US7544784B2 (en) 2001-02-23 2009-06-09 Immunex Corporation Increased recovery of active proteins
US7157557B2 (en) 2001-02-23 2007-01-02 Immunex Corporation Increased recovery of active proteins
WO2002068455A3 (en) * 2001-02-23 2003-09-18 Immunex Corp Efficient recovery of correctly refolded proteins
WO2003011323A1 (en) * 2001-07-30 2003-02-13 Genset S.A. Agonists and antagonists of contabix for use in the treatment of metabolic disorders
US7964712B2 (en) 2001-12-06 2011-06-21 The Regents Of The University Of California Chimeric nucleic acids encoding polypeptides comprising TNF alpha, CD70 and FAS ligand domains
US7674453B2 (en) 2002-02-06 2010-03-09 Ares Trading Sa Tumor necrosis factor combined with interferon in demyelinating diseases
US7928205B2 (en) 2004-10-22 2011-04-19 Amgen Inc. Methods for refolding of recombinant antibodies
WO2016029043A1 (en) 2014-08-21 2016-02-25 The General Hospital Corporation Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same

Also Published As

Publication number Publication date
EP0772449A1 (en) 1997-05-14
JPH09508140A (ja) 1997-08-19
FI970247A0 (fi) 1997-01-21
AU3111995A (en) 1996-02-22
CA2195665A1 (en) 1996-02-08
CZ283219B6 (cs) 1998-02-18
PL318501A1 (en) 1997-06-23
NO970264D0 (no) 1997-01-21
NO970264L (no) 1997-03-24
BR9508419A (pt) 1997-11-18
FI970247A (fi) 1997-01-21
CZ19397A3 (en) 1997-06-11
HUT76666A (en) 1997-10-28

Similar Documents

Publication Publication Date Title
EP0772449A1 (en) Pharmaceutical compositions comprising a chimaeric tnf binding protein
Körner et al. Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system
KR100493482B1 (ko) T세포매개된자가면역질환의치료방법
JP6526872B2 (ja) 関節リウマチの治療のための可溶性ｃｄ２４の使用方法
WO1998022137A1 (en) SUPPRESSION OF TNF α AND IL-12 IN THERAPY
US20150044245A1 (en) Partial mhc constructs and methods of use
WO1995003827A1 (en) Method for treating multiple sclerosis
US20020058627A1 (en) Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein
KR100694507B1 (ko) 항-4-1ｂｂ 항체를 포함하는 류마티스성 관절염의 예방 및치료용 약학 조성물
EP1423138B1 (en) Use of il-18 inhibitors in hypersensitivity disorders
AU2002331376A1 (en) Use of IL-18 inhibitors in hypersensitivity disorders
Steinman et al. Therapy of Autoimmune Diseases Using Antibodies to Molecules of the Major Histocompatibility Complex
Bhat et al. Experimental Therapies with T-Cell Vaccines, Oral Myelin, and Monoclonal Antibodies in Multiple Sclerosis
AU3685899A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 95194299.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KP KR KZ LK LR LT LV MD MG MN MX NO NZ PL RO RU SG SI SK TJ TM TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995926902

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2195665

Country of ref document: CA

Ref document number: 970247

Country of ref document: FI

Ref document number: PV1997-193

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1995926902

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1997 776092

Country of ref document: US

Date of ref document: 19970529

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: PV1997-193

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: PV1997-193

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1995926902

Country of ref document: EP